NewsHK
Clinical trial outcomes are the sharpest single-session repricing events in large-cap pharma.
On Tuesday, three of them moved against Novartis at once, sending shares nearly 10% lower and putting the stock on course for its worst day on record.
Results from the del-desiran programme were the named catalyst for the selling. When pipeline breadth stops cushioning Large-cap pharma valuations carry an implicit premium for diversified pipelines.
The standard argument is that a wide portfolio of programmes absorbs any one failure without threatening the broader thesis. Three setbacks landing in a single session compress that argument abruptly.
Keep reading